Literature DB >> 16869749

The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.

W G Kaelin1.   

Abstract

Biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is a common event in hereditary (von Hippel- Lindau disease) and sporadic hemangioblastomas and clear-cell renal carcinomas. Germ-line VHL mutations are also linked to some hereditary pheochromocytoma families. The VHL gene product, pVHL, interacts with a number of cellular proteins and is implicated in the control of angiogenesis, extracellular matrix formation, cell metabolism, and mitogenesis. The best understood function of pVHL relates to its role as the substrate recognition unit of an E3 ligase that targets the heterodimeric transcription factor HIF (hypoxia-inducible factor) for destruction in the presence of oxygen. Down-regulation of HIF appears to be both necessary and sufficient for renal tumor suppression by pVHL, and HIF is strongly suspected of contributing to hemangioblastoma development as well. Recent work suggests that pVHL's role in pheochromocytoma is not related to HIF but rather to the ability of pVHL to regulate neuronal apoptosis, which is mediated by c-Jun, when growth factors such as NGF become limiting. Loss of pVHL leads to up-regulation of JunB, which antagonizes c-Jun and blunts apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869749     DOI: 10.1101/sqb.2005.70.001

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  26 in total

Review 1.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

Review 2.  Nucleoside diphosphate kinases (NDPKs) in animal development.

Authors:  Krisztina Takács-Vellai; Tibor Vellai; Zsolt Farkas; Anil Mehta
Journal:  Cell Mol Life Sci       Date:  2014-12-24       Impact factor: 9.261

3.  The Wnt Signaling Antagonist Dapper1 Accelerates Dishevelled2 Degradation via Promoting Its Ubiquitination and Aggregate-induced Autophagy.

Authors:  Benyu Ma; Bofeng Liu; Weipeng Cao; Chan Gao; Zhen Qi; Yuanheng Ning; Ye-Guang Chen
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

Review 4.  Alterations in VHL as potential biomarkers in renal-cell carcinoma.

Authors:  Lucy Gossage; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 5.  Signaling pathways in renal cell carcinoma.

Authors:  Gowrishankar Banumathy; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

6.  miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity.

Authors:  M-P Puisségur; N M Mazure; T Bertero; L Pradelli; S Grosso; K Robbe-Sermesant; T Maurin; K Lebrigand; B Cardinaud; V Hofman; S Fourre; V Magnone; J E Ricci; J Pouysségur; P Gounon; P Hofman; P Barbry; B Mari
Journal:  Cell Death Differ       Date:  2010-10-01       Impact factor: 15.828

7.  MicroRNA-21-5p induces the metastatic phenotype of human cervical carcinoma cells in vitro by targeting the von Hippel-Lindau tumor suppressor.

Authors:  Lina Cai; Wuliang Wang; Xiaomei Li; Tieli Dong; Qing Zhang; Baojv Zhu; Hu Zhao; Shubiao Wu
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

8.  The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.

Authors:  Sophie Beyer; Malene Maag Kristensen; Kim Steen Jensen; Jens Vilstrup Johansen; Peter Staller
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

Review 9.  Hypoxia, glucose metabolism and the Warburg's effect.

Authors:  Ramon Bartrons; Jaime Caro
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

Review 10.  Actuality of Warburg's views in our understanding of renal cancer metabolism.

Authors:  Catherine Godinot; Elodie de Laplanche; Eric Hervouet; Hélène Simonnet
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.